{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Number of participants who experienced a grade 3-5 adverse event in the dose expansion group","groups":[{"description":"Patients receive pevonedistat the maximum tolerated dose (MTD) as determined in the dose escalation phase by infusion ande ixazomib citrate 4 mg by mouth on days 1, 8, and 15 of each 28-day cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Dose Expansion"}],"populationDescription":"Did not complete dose escalation phase to enroll to the dose expansion phase.","reportingStatus":"POSTED","timeFrame":"Up to 2 years after Treatment","title":"Number of Participants Experiencing a Grade 3-5 Adverse Event (Dose Expansion)","type":"PRIMARY"}